Disclosed is a compound of formula (I) as depicted where the substituents are as disclosed in the specification. Examples of compounds of formula (I) are 5-Cyano-1-(2,4-dimethoxypheriylsulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yI 4-(4-methylpiperazin-1-yI)benzoate N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1 -yl)benzamide N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-(4-methoxyphenylsulfonyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yI)benzamide. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament for treatment and/or prophylaxis of vasopressin-dependent diseases such as diabetes, insulin resistance, nocturnal enuresis, incontinence hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina affective disorders anxiety disorders and stress-dependent anxiety disorders impairments and Alzheimers disease psychoses and psychotic disorders Cushings syndrome and other stress-dependent diseases sleep disorders depressive disorders childhood onset mood disorders symptoms and/or thermoregulatory dysfunctions drug or pharmaceutical dependencies and schizophrenia.
